Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06072170 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience
A Phase 1 study of Pharmacokinetics and Safety, sponsored by Altasciences Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06072170 is a Phase 1 study of Pharmacokinetics and Safety that has completed, run by Altasciences Company. The registered enrollment target is 40 participants, below the 61-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06072170, a Phase 1 study of Pharmacokinetics and Safety, has completed, sponsored by Altasciences Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Kratom (Mitragyna speciosa) is a plant often used to self-treat conditions such as pain, coughing, diarrhea, anxiety and depression, opioid use disorder, and opioid withdrawal. Due to limited data availability, the goal of this clinical trial is to learn about safety, pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body) of Kratom in adult recreational polydrug users with opioid experience.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Kratom
Study Locations (1)
Kansas
- Altasciences Clinical Kansas, Inc. - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-08-16 |
| Est. Completion | 2024-01-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06072170
The ClinicalTrials.gov registry entry for NCT06072170 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (34% lower). The listed sponsor is Altasciences Company, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pharmacokinetics appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06072170 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT06072170 about?
NCT06072170 is a clinical study titled "Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience". Kratom (Mitragyna speciosa) is a plant often used to self-treat conditions such as pain, coughing, diarrhea, anxiety and depression, opioid use disorder, and opioid withdrawal. Due to limited data availability, the goal of this clinical trial is to learn about safety, pharmacokinetics (what the body...
What is the current status of trial NCT06072170?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-08-16. Estimated completion is 2024-01-23.
What conditions does trial NCT06072170 study?
This clinical trial studies the following conditions: Pharmacokinetics, Safety, Pharmacodynamics.
What interventions are being tested in trial NCT06072170?
The interventions under investigation include: Placebo (DRUG), Kratom (DRUG).
Who is sponsoring clinical trial NCT06072170?
This trial is sponsored by Altasciences Company, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06072170 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacokinetics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
RECRUITING · Phase 1
-
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RECRUITING · Phase 1
-
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
RECRUITING · Phase 1
-
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.